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Developmental origins of mosaicism
Chromosomal mosaicism is defined as the presence of 
two or more karyotypically different cell lines in the same 
individual. Somatic mosaicism mostly results from post-
zygotic  errors  in  recombination  or  replication.  Whole 
chromo  somal aneuploidies (in which there are more than 
or fewer than two copies of one or more chromosomes) 
can  arise  by  non-disjunction  or  anaphase  lagging. 
Imbalances of chromosomal segments can originate from 
unrepaired breakages.
Chromosome instability is common in human cleavage-
stage embryos that have been fertilized in vitro. This has 
become more apparent through the application of new 
techniques for the analysis of the chromosome content of 
single  blastomeres.  Recent  array  comparative  genomic 
hybridization  (array  CGH)  analysis  [1]  of  normally 
developing,  good  quality  preimplantation  embryos 
confirmed the presence of a high percentage of chromo-
somal abnormalities at cleavage stage. In addition, this 
analysis  [1]  showed  that  all  abnormal  embryos  were 
mosaic for the aberrations found and that not only could 
whole chromosome aneuploidies be detected, but also a 
significant  number  of  segmental  aberrations.  Most  of 
these embryos are selected against during the first days 
and weeks of gestation. As a consequence mosaicism is 
observed  in  just  5%  of  aneuploid  spontaneous  mis-
carriages between 6 and 20 weeks [2] and in only 1 to 2% 
of  viable  pregnancies  screened  by  chorionic  villus 
sampling [3,4].
The role of somatic mosaicism in disease
Somatic mosaicism contributes to variations in pheno-
typic expression and disease and has important clinical 
consequences.  Constitutional  chromosomal  mosaicism 
has been implicated as a cause of several well described 
genetic  syndromes.  The  best  characterized  mosaic 
syndrome is Pallister-Killian syndrome. This syndrome is 
a  clinically  recognizable,  multiple  malformation  syn-
drome with distinct facial features and is often associated 
with  a  diaphragmatic  hernia  that  can  lead  to  neonatal 
death. It is caused by the presence of an isochromosome 
12p, which is an abnormal extra chromosome consisting 
of two copies of the short arm of chromosome 12 fused at 
the  centromere,  resulting  in  tetrasomy  12p  [5,6].  This 
isochromosome is mainly observed in fibroblasts but is 
found  in  only  very  low  numbers  in  circulating  blood 
lymphocytes [7]. Other such small supernumerary marker 
chromosomes, defined as structurally abnormal chromo-
somes that cannot be identified or characterized unam-
bigu  ously by conventional banding techniques alone, are 
also present in only a subset of cells in the majority of 
affected  individuals  [8].  In  addition,  almost  all  known 
chromosomal anomalies have been detected in a mosaic 
state in occasional patients [9].
The  presence  of  such  low-level  mosaic  chromosome 
abnormalities  has  also  been  linked  to  several  multi-
factorial diseases. It has, for example, been implicated as 
a genetic risk factor in children with syndromic autism 
[10,11].  Moreover,  mosaic  gains  or  losses  of  whole 
chromosomes  have  recently  been  described  in  the 
human brain [12,13] and may contribute to certain brain 
patho  lo  gies,  such  as  schizophrenia  and  Alzheimer’s 
disease [14,15].
Mosaicisms are also important in acquired disorders. 
Cancer is one of the most prominent forms of somatic 
mosaicism, and chromosomal copy-number aberrations 
are a frequent finding in solid tumors [16]. The organism 
affected with such an alteration is a somatic mosaic, in 
which the cancerous tissue often has a different genetic 
constitution from the rest of the body.
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The true incidence of chromosomal mosaicism causing 
significant phenotypic effects is unknown but is probably 
greater than 1 in 10,000. It seems likely, however, that 
chromosomal  mosaicism  is  underdiagnosed,  for  two 
main reasons [17]. First, unless some phenotypic clues 
(such as discrepancies in body symmetry, pigmentation 
or  facial  appearance)  indicate  the  presence  of  mosaic 
somatic changes, their occurrence often goes undetected. 
A  study  on  phenotypically  ‘normal’  individuals  using 
multi  plex  PCR  of  seven  simple,  short  tandem  repeats 
showed that trisomies and translocations at each locus 
examined  occurred  with  an  incidence  of  1  in  2,000 
samples  [18,19].  Identification  of  somatic  mosaicism  is 
also clearly hampered by the process of tissue sampling. 
Aberrations that formed at particular stages of develop-
ment might be present only in a specific tissue (such as 
brain tissue or fibroblasts) and could easily be missed in a 
blood karyotype.
Low-level mosaicisms have long been recognized and 
were first identified by karyotyping. A common routine 
test  analyzes  20  metaphases  from  stimulated  T-cell 
cultures, and this enables the detection of an abnormality 
in 21% or more of the cells with 99% confidence [20]. If 
the  percentage  of  affected  cells  is  smaller,  they  can  be 
missed, interpreted as normal variation in the population 
or  dismissed  as  a  culture  artifact.  Several  studies  have 
shown  that  there  is  preferential  growth  of  the  normal 
cells in stimulated blood cultures, leading to an under-
estimation of the percentage of abnormal cells or to the 
aberration going completely undetected [21-23].
The  introduction  of  fluorescent  in  situ  hybridization 
(FISH) enabled the analysis of large numbers of cells at a 
higher  resolution  (about  80  to  200  kilobases)  [24]  and 
lower-level  mosaicisms  could  thereby  be  detected. 
Unfortunately, FISH looks at only a single specific locus 
and mosaicism of this locus must therefore be suspected 
beforehand. With the use of array CGH, genome-wide 
analysis  of  mosaic  imbalances  has  become  a  routine 
possibility. Several cases of mosaicism have been detected 
by array CGH [21,22]. Low-level mosaicisms have been 
described in constitutional disorders, with abnormal cells 
making up 7 to 30% of cells [22,23,25-27], as well as in 
cancers [28-30]. The first reports on array CGH showed 
the  ability  to  detect  low-level  mosaics,  and  sporadic 
reports  show  that  mosaicism  as  low  as  5%  can  be 
detected by bacterial artificial chromosome (BAC)-based 
array CGH [23]. Studies investigating the lower detection 
limits show that BAC and oligonucleotide arrays enable 
the detection of 10 to 20% of mosaicisms in a systematic 
way [21,31]. However, these percentages are reached only 
if dye swap experiments are performed and no threshold 
filters are applied, as the deviance from zero might be 
subtle [31].
The future: improvements and applications
Further increases in sensitivity are warranted for a better 
diagnosis. First, some smaller copy-number variants can 
be present in a mosaic form. Second, some aneuploidies 
can be present in a small minority of the blood cells, the 
tissue on which tests are most often performed, but can 
be  present  in  higher  numbers  in  other  tissues.  For 
example, the identification of a small percentage of iso-
chromosome 12p in blood cells can enable the diagnosis 
of Pallister-Killian syndrome.
Finally,  methods  used  in  the  detection  of  low  grade 
mosaics may open up new areas of diagnosis in other 
fields.  For  example,  DNA  in  the  plasma  of  cancer 
patients  contains  circulating  DNA  derived  from  the 
tumor, which might be distinguished from normal DNA 
by such methods. Equally, it might become possible to 
detect  fetal  aneuploidies  by  screening  the  plasma  of 
pregnant  women.  The  ability  to  detect  this  DNA  by 
genome-wide  screening  methods  would  open  new 
diagnostic possibilities.
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